Advertisement
UK markets closed

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     

  • AIM

    789.87
    +6.17 (+0.79%)
     

  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     

  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     

  • Bitcoin GBP

    48,693.73
    -1,473.92 (-2.94%)
     

  • CMC Crypto 200

    1,262.99
    -95.02 (-7.00%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     
MONEY:

Best savings accounts that offer above inflation rates

How to earn the most interest on your savings

BUZZ-Shire: best day in 16 months on dry eye drug breakthrough

Reuters - UK Focus

** Shire (Xetra: S7E.DE - news) jumps 6.6%, on course for biggest one-day rise since June 2014, and by far and away top riser on FTSE 100

** Dry eye disease drug, which is called Lifitegrast, meets primary endpoints

** CEO says that if Lifitegrast approved by FDA, on track for US launch next year

** Shares (Berlin: DI6.BE - news) hit recently when FDA decided not to approve Lifitegrast, asked for further clinical data (RM (LSE: RM.L - news) : tricia.wright1.thomsonreuters.com@reuters.net)